254 related articles for article (PubMed ID: 25650331)
1. Computer-aided assessment of hepatic contour abnormalities as an imaging biomarker for the prediction of hepatocellular carcinoma development in patients with chronic hepatitis C.
Goshima S; Kanematsu M; Kondo H; Watanabe H; Noda Y; Fujita H; Bae KT
Eur J Radiol; 2015 May; 84(5):811-5. PubMed ID: 25650331
[TBL] [Abstract][Full Text] [Related]
2. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
3. Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients.
Li X; Xu H; Gao P
Med Sci Monit; 2019 Sep; 25():7243-7250. PubMed ID: 31558693
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients.
Tamaki N; Kurosaki M; Matsuda S; Muraoka M; Yasui Y; Suzuki S; Hosokawa T; Ueda K; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
J Gastroenterol; 2014 Nov; 49(11):1495-503. PubMed ID: 24337828
[TBL] [Abstract][Full Text] [Related]
5. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.
El-Serag HB; Kanwal F; Davila JA; Kramer J; Richardson P
Gastroenterology; 2014 May; 146(5):1249-55.e1. PubMed ID: 24462733
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
7. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
8. Fibro-Mark: a panel of laboratory parameters for predicting significant fibrosis in chronic hepatitis C patients.
Attallah AM; Omran D; Omran MM; Albannan MS; Zayed RA; Saif S; Farid A; Hassany M; Yosry A
Br J Biomed Sci; 2018 Jan; 75(1):19-23. PubMed ID: 28945150
[TBL] [Abstract][Full Text] [Related]
9. Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index.
Nartey YA; Awuku YA; Agyei-Nkansah A; Duah A; Bampoh SA; Ayawin J; Asibey SO; Björkström NK; Ye W; Afihene MY; Roberts LR; Plymoth A
BMC Gastroenterol; 2020 Dec; 20(1):428. PubMed ID: 33357229
[TBL] [Abstract][Full Text] [Related]
10. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
11. Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte-phase image is a risk factor for hypervascular hepatocellular carcinoma.
Ichikawa S; Ichikawa T; Motosugi U; Sano K; Morisaka H; Enomoto N; Matsuda M; Fujii H; Araki T
J Magn Reson Imaging; 2014 Feb; 39(2):293-7. PubMed ID: 23633285
[TBL] [Abstract][Full Text] [Related]
12. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients.
Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Tanaka J
J Gastroenterol Hepatol; 2013 Feb; 28(2):357-64. PubMed ID: 23190084
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of alpha-fetoprotein in chronic hepatitis C.
Tai WC; Hu TH; Wang JH; Hung CH; Lu SN; Changchien CS; Lee CM
J Formos Med Assoc; 2009 Mar; 108(3):210-8. PubMed ID: 19293036
[TBL] [Abstract][Full Text] [Related]
17. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.
Giannini EG; Sammito G; Farinati F; Ciccarese F; Pecorelli A; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Gasbarrini A; Sacco R; Foschi FG; Missale G; Morisco F; Svegliati Baroni G; Virdone R; Trevisani F;
Cancer; 2014 Jul; 120(14):2150-7. PubMed ID: 24723129
[TBL] [Abstract][Full Text] [Related]
18. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
19. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals.
Casadei Gardini A; Foschi FG; Conti F; Petracci E; Vukotic R; Marisi G; Buonfiglioli F; Vitale G; Ravaioli F; Gitto S; Verucchi G; Lenzi M; Bolondi L; Mazzella G; Brillanti S; Andreone P;
Dig Liver Dis; 2019 May; 51(5):681-688. PubMed ID: 30327251
[TBL] [Abstract][Full Text] [Related]
20. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
